This article was written at the end of last year prior to the recent IPO. One thing of interest is the 20 year sale agreement with Zimmer Biomet (market cap $24.55 Billion) and the worldwide distribution agreement with 3M ($126.05 Billion). I also note that there is a forecast of $20 million sales for 2019 which was not on the current prospectus for various reasons. But if the trajectory is true this would potentially represent revenue growth of over 600% vs 2018 revenue. DYOR and GLTAH!
How the rich invest: Lang Walker backs Next Science's bacteria buster
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.005(2.13%) |
Mkt cap ! $70.11M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.3¢ | $3.257K | 13.57K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6601 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 145820 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NXS (ASX) Chart |